5

15

20



## What is claimed:

- 1. An isolated HIV envelope protein or fragment thereof which, when adminsitered to a pammal, induces the production of broadly cross-reactive neutralizing anti-serum against multiple strains of HIV-1.
  - 2. An isolated HIV envelope protein comprising the amino acid sequence of SEQ ID NO:1.
- 3. An isolated HIV envelope protein or fragment thereof comprising a proline at a position corresponding to amino acid residue 313, a methionine at a position corresponding to amino acid residue 314 and a glutamine at a position corresponding to amino acid residue 325 of SEQ ID NO:1.
  - 4. An isolated HIV envelope protein or fragment thereof comprising a V3 region having the amino acid sequence P M  $X_1$   $X_2$   $X_3$   $X_4$   $X_5$   $X_6$   $X_7$   $X_8$   $X_9$   $X_{10}$  Q, wherein  $X_1$ - $X_{10}$  are a natural or non-natural amino acid.
  - 5. A vaccine composition comprising an isolated HIV-1 envelope protein or fragment thereof of any one of claims 1-4 and a pharmaceutically acceptable carrier.
  - 6. An immunogenic composition comprising an isolated HIV-1 envelope protein or fragment thereof of any one of claims 1-4 and a pharmaceutically acceptable carrier.
- 7. An isolated nucleic acid molecule encoding the HIV-1 envelope protein or fragment thereof of any of claims 1-4.
  - 8. A fusion protein comprising all or a portion of a microbiological antigen into which any one of the proteins of claims 1-4 has been inserted.

30

9. A recombinant delivery vector encoding a fusion protein comprising all or a portion of a microbiological antigen into which any one of the proteins of claims 1-4 has been inserted.

- 5 10. A vaccine composition comprising any one of the recombinant delivery vectors of claim 9 and a pharmaceutically acceptable carrier.
  - 11. An immunogenic composition comprising any one of the recombinant delivery vectors of claim 9 and a pharmaceut cally acceptable carrier.

10

12. A recombinant delivery vector encoding an attenuated virus further comprising a nucleotide sequence encoding one or more of the proteins of any one of claims 1-4.

15

And the same

13. The recombinant delivery vector of claim 12 wherein the attenuated virus is selected from the group comprising HIV, encepalitis virus, poliovirus, poxvirus and vaccinia virus.

20

14. A vaccine composition comprising any one of the recombinant delivery vectors of claim 12 and a pharmaceutically acceptable carrier.

15. An immunogenic composition comprising any one of the recombinant delivery vectors of claim 12 and a pharmaceutically acceptable carrier.

<sup>25</sup>

16. A method of generating antibodies in a mammal comprising administering one or more of the proteins or fragments thereof of any one of claims 1-4, in an amount sufficient to induce the production of the antibodies.


30

17. A/method of generating antibodies in a mammal comprising administering a

DNA or mRNA sequence encoding any one of the proteins or fragments thereof of claims

1-4, in an amount sufficient to induce the production of the antibodies.

18. The method of claim 17, wherein said DNA is naked DNA.



19. A diagnostic reagent comprising one or more of the isolated HIV-1-envelope-proteins or fragments thereof of any one of claims 1-4.

- 20. A method of detecting HIV-1 antibodies in a sample comprising the step of determining whether antibodies in the sample bind to one or more of the HIV-1 envelope proteins or fragments thereof of claims 1-4.
  - 21. A cyclic peptide comprising the amino acid sequence of either claims 3 or 4.
  - 22. Artisolated antibody which specifically recognizes the protein of claims 3 or

The first that the fine and that

15

4.

10